USPTO Reaffirms Solodyn Patent

Law360, New York (June 3, 2010, 3:16 PM EDT) -- Medicis Pharmaceutical Corp. has secured a re-examination certificate holding that several patent claims for the company's acne treatment Solodyn are patentable over certain prior art.

The skin health specialist said Tuesday that the U.S. Patent and Trademark Office had issued a re-exam certificate reaffirming its patent, U.S. Patent Number 5,908,838, which has been asserted in several infringement suits, according to a Form 8-K filing with the U.S. Securities and Exchange Commission.

The USPTO signed off on claims 3, 4, 12 and 13, as well as new...
To view the full article, register now.